Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen

Yoshikazu Yonemitsu, Yasuji Ueda, Hiroaki Kinoh, Mamoru Hasegawa

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The utility of recombinant Sendai virus (rSeV) has been considerably examined over the last decade as a potent gene transfer candidate in a cytoplasmic gene expression system. Such risks as excessive immune responses associated with this virus administration in vivo however have limited its applicability in clinical settings as is the case with other viral vectors including adenoviruses. In consequence of extensive assessment on the mechanisms of immune responses against SeV, we found that ex vivo infection of immature dendritic cells (DCs) with SeV demonstrates their spontaneous maturation and activation. We applied this result to create a unique, representative, and powerful agent to activate DCs, namely rSeV-modified DCs (rSeV/DCs), for use in cancer immunotherapy. Use of this system in vivo resulted in the induction of efficient antitumor immunity against vascularized rodent tumors, including melanoma, hepatocellular carcinoma, neuroblastoma, squamous cell carcinoma, and prostatic cancer, and it even frequently associated with elimination of those tumors. These results indicate that rSeV could be a powerful immune booster for DC-based cancer immunotherapy that is worth investigating further. We propose a conceptual term "immunostimulatory virotherapy" to describe this new method of cancer therapy using the rSeV/DCs system.

Original languageEnglish
Pages (from-to)1892-1898
Number of pages7
JournalFrontiers in Bioscience
Volume13
Issue number5
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Sendai virus
Viruses
Dendritic Cells
Neoplasms
Immunotherapy
Tumors
Gene transfer
Satellite Viruses
Therapeutics
Squamous Cell Neoplasms
Neuroblastoma
Adenoviridae
Gene expression
Hepatocellular Carcinoma
Squamous Cell Carcinoma
Immunity
Rodentia
Melanoma
Prostatic Neoplasms
Chemical activation

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology
  • Medicine(all)

Cite this

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. / Yonemitsu, Yoshikazu; Ueda, Yasuji; Kinoh, Hiroaki; Hasegawa, Mamoru.

In: Frontiers in Bioscience, Vol. 13, No. 5, 2008, p. 1892-1898.

Research output: Contribution to journalReview article

Yonemitsu, Yoshikazu ; Ueda, Yasuji ; Kinoh, Hiroaki ; Hasegawa, Mamoru. / Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. In: Frontiers in Bioscience. 2008 ; Vol. 13, No. 5. pp. 1892-1898.
@article{88d09d8082f94a82ab6062cb9fa55980,
title = "Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen",
abstract = "The utility of recombinant Sendai virus (rSeV) has been considerably examined over the last decade as a potent gene transfer candidate in a cytoplasmic gene expression system. Such risks as excessive immune responses associated with this virus administration in vivo however have limited its applicability in clinical settings as is the case with other viral vectors including adenoviruses. In consequence of extensive assessment on the mechanisms of immune responses against SeV, we found that ex vivo infection of immature dendritic cells (DCs) with SeV demonstrates their spontaneous maturation and activation. We applied this result to create a unique, representative, and powerful agent to activate DCs, namely rSeV-modified DCs (rSeV/DCs), for use in cancer immunotherapy. Use of this system in vivo resulted in the induction of efficient antitumor immunity against vascularized rodent tumors, including melanoma, hepatocellular carcinoma, neuroblastoma, squamous cell carcinoma, and prostatic cancer, and it even frequently associated with elimination of those tumors. These results indicate that rSeV could be a powerful immune booster for DC-based cancer immunotherapy that is worth investigating further. We propose a conceptual term {"}immunostimulatory virotherapy{"} to describe this new method of cancer therapy using the rSeV/DCs system.",
author = "Yoshikazu Yonemitsu and Yasuji Ueda and Hiroaki Kinoh and Mamoru Hasegawa",
year = "2008",
doi = "10.2741/2809",
language = "English",
volume = "13",
pages = "1892--1898",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "5",

}

TY - JOUR

T1 - Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen

AU - Yonemitsu, Yoshikazu

AU - Ueda, Yasuji

AU - Kinoh, Hiroaki

AU - Hasegawa, Mamoru

PY - 2008

Y1 - 2008

N2 - The utility of recombinant Sendai virus (rSeV) has been considerably examined over the last decade as a potent gene transfer candidate in a cytoplasmic gene expression system. Such risks as excessive immune responses associated with this virus administration in vivo however have limited its applicability in clinical settings as is the case with other viral vectors including adenoviruses. In consequence of extensive assessment on the mechanisms of immune responses against SeV, we found that ex vivo infection of immature dendritic cells (DCs) with SeV demonstrates their spontaneous maturation and activation. We applied this result to create a unique, representative, and powerful agent to activate DCs, namely rSeV-modified DCs (rSeV/DCs), for use in cancer immunotherapy. Use of this system in vivo resulted in the induction of efficient antitumor immunity against vascularized rodent tumors, including melanoma, hepatocellular carcinoma, neuroblastoma, squamous cell carcinoma, and prostatic cancer, and it even frequently associated with elimination of those tumors. These results indicate that rSeV could be a powerful immune booster for DC-based cancer immunotherapy that is worth investigating further. We propose a conceptual term "immunostimulatory virotherapy" to describe this new method of cancer therapy using the rSeV/DCs system.

AB - The utility of recombinant Sendai virus (rSeV) has been considerably examined over the last decade as a potent gene transfer candidate in a cytoplasmic gene expression system. Such risks as excessive immune responses associated with this virus administration in vivo however have limited its applicability in clinical settings as is the case with other viral vectors including adenoviruses. In consequence of extensive assessment on the mechanisms of immune responses against SeV, we found that ex vivo infection of immature dendritic cells (DCs) with SeV demonstrates their spontaneous maturation and activation. We applied this result to create a unique, representative, and powerful agent to activate DCs, namely rSeV-modified DCs (rSeV/DCs), for use in cancer immunotherapy. Use of this system in vivo resulted in the induction of efficient antitumor immunity against vascularized rodent tumors, including melanoma, hepatocellular carcinoma, neuroblastoma, squamous cell carcinoma, and prostatic cancer, and it even frequently associated with elimination of those tumors. These results indicate that rSeV could be a powerful immune booster for DC-based cancer immunotherapy that is worth investigating further. We propose a conceptual term "immunostimulatory virotherapy" to describe this new method of cancer therapy using the rSeV/DCs system.

UR - http://www.scopus.com/inward/record.url?scp=38449087528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449087528&partnerID=8YFLogxK

U2 - 10.2741/2809

DO - 10.2741/2809

M3 - Review article

VL - 13

SP - 1892

EP - 1898

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 5

ER -